Smith, Moore & Co’s Lifecore Biomedical LFCR Stock Holding History

Smith, Moore & Co’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,000	Closed	-$45.3K	–	406
2023 Q1	$45.3K	Buy	+12,000	New	+$66.9K	0.01%	383
2022 Q4	–	Sell	-10,500	Closed	-$93K	–	378
2022 Q3	$93K	Hold	10,500	–	–	0.01%	371
2022 Q2	$105K	Sell	10,500 -500	-5%	-$4.95K	0.02%	381
2022 Q1	$127K	Buy	11,000 +1,000	+10%	+$11.1K	0.02%	405
2021 Q4	$111K	Buy	+10,000	New	+$97K	0.02%	407

Other funds holding LFCR

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Smith, Moore & Co's LFCR Position: Q2 2023 in Review

Smith, Moore & Co sold out of Lifecore Biomedical (LFCR) in Q2 2023, closing a stake of 12,000 shares — an estimated $45.3K sold.

Smith, Moore & Co first reported a position in LFCR in Q4 2021 and held it in 5 quarters. The position peaked at $127K in Q1 2022. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2023.

Smith, Moore & Co reported no remaining Lifecore Biomedical position as of Q2 2023 after selling out during the quarter.
Smith, Moore & Co sold 12,000 Lifecore Biomedical shares in Q2 2023, an estimated $45.3K.
Smith, Moore & Co first reported a position in Lifecore Biomedical in Q4 2021 and held it in 5 quarters.
Smith, Moore & Co's Lifecore Biomedical position peaked at $127K in Q1 2022.
75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2023.

Based on Smith, Moore & Co's 13F filing for Q2 2023, filed 11 Aug 2023.